Rational Design of Small Molecule Inhibitors Targeting the Ras GEF, SOS1

被引:47
|
作者
Evelyn, Chris R. [1 ]
Duan, Xin [1 ]
Biesiada, Jacek [2 ]
Seibel, William L. [3 ]
Meller, Jaroslaw [2 ,4 ]
Zheng, Yi [1 ]
机构
[1] Childrens Hosp Res Fdn, Div Expt Hematol & Canc Biol, Cincinnati, OH 45229 USA
[2] Childrens Hosp Res Fdn, Div Biomed Informat, Cincinnati, OH 45229 USA
[3] Childrens Hosp Res Fdn, Div Oncol, Cincinnati, OH 45229 USA
[4] Univ Cincinnati, Dept Environm Hlth, Cincinnati, OH 45267 USA
来源
CHEMISTRY & BIOLOGY | 2014年 / 21卷 / 12期
关键词
GUANINE-NUCLEOTIDE EXCHANGE; MICROSCALE THERMOPHORESIS; NOONAN-SYNDROME; ONCOGENIC RAS; K-RAS; ACTIVATION; FLUORESCENCE; GAIN; GTP; PHOSPHORYLATION;
D O I
10.1016/j.chembiol.2014.09.018
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Ras GTPases regulate intracellular signaling involved in cell proliferation. Elevated Ras signaling activity has been associated with human cancers. Ras activation is catalyzed by guanine nucleotide exchange factors (GEFs), of which SOS1 is a major member that transduces receptor tyrosine kinase signaling to Ras. We have developed a rational approach coupling virtual screening with experimental screening in identifying small-molecule inhibitors targeting the catalytic site of SOS1 and SOS1-regulated Ras activity. A lead inhibitor, NSC-658497, was found to bind to SOS1, competitively suppress SOS1-Ras interaction, and dose-dependently inhibit SOS1 GEF activity. Mutagenesis and structure-activity relationship studies map the NSC-658497 site of action to the SOS1 catalytic site, anddefine the chemical moieties in the inhibitor essential for the activity. NSC-658497 showed dose-dependent efficacy in inhibiting Ras, downstream signaling activities, and associated cell proliferation. These studies establish a proof of principle for rational design of small-molecule inhibitors targeting Ras GEF enzymatic activity.
引用
收藏
页码:1618 / 1628
页数:11
相关论文
共 50 条
  • [21] Rational design of small molecule RHOA inhibitors for gastric cancer
    Kim, Jin-Hee
    Park, Sungjin
    Lim, Seung Mook
    Eom, Hyo Jin
    Balch, Curt
    Lee, Jinhyuk
    Kim, Gi Jin
    Jeong, Jin-Hyun
    Nam, Seungyoon
    Kim, Yon Hui
    PHARMACOGENOMICS JOURNAL, 2020, 20 (04): : 601 - 612
  • [22] CIIA functions as a molecular switch for the Rac1-specific GEF activity of SOS1
    Hwang, Hyun Sub
    Hwang, Sang Gil
    Cho, Jun-Ho
    Chae, Ji Soo
    Yoon, Kyoung Wan
    Cho, Ssang-Goo
    Choi, Eui-Ju
    JOURNAL OF CELL BIOLOGY, 2011, 195 (03): : 377 - 386
  • [23] Small Molecule-Mediated Activation of RAS Elicits Biphasic Modulation of Phospho-ERK Levels that Are Regulated through Negative Feedback on SOS1
    Howes, Jennifer E.
    Akan, Denis T.
    Burns, Michael C.
    Rossanese, Olivia W.
    Waterson, Alex G.
    Fesik, Stephen W.
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (05) : 1051 - 1060
  • [24] Rational Design of Small Molecule Immune Checkpoints' Inhibitors: The PD-1 Challenge
    Barakat, Khaled
    JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 2017, 20 : 9S - 10S
  • [25] SOS1 OVER-EXPRESSION IN GENITAL SKIN FIBROBLASTS FROM HIRSUTE WOMEN: A PUTATIVE ROLE OF THE SOS1/RAS PATHWAY IN THE PATHOGENESIS OF HIRSUTISM
    Minella, D.
    Wannenes, F.
    Biancolella, M.
    Amati, F.
    Testa, B.
    Nardone, A.
    Bueno, S.
    Fabbri, A.
    Lauro, D.
    Novelli, G.
    Moretti, C.
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2011, 25 (04): : 615 - 626
  • [26] Discovery of novel SOS1 inhibitors using machine learning
    Duo, Lihui
    Chen, Yi
    Liu, Qiupei
    Ma, Zhangyi
    Farjudian, Amin
    Ho, Wan Yong
    Low, Sze Shin
    Ren, Jianfeng
    Hirst, Jonathan D.
    Xie, Hua
    Tang, Bencan
    RSC MEDICINAL CHEMISTRY, 2024, 15 (04): : 1392 - 1403
  • [27] Single Molecule Processivity of SOS-cat, the Catalytic Core of the Ras Gef 'son of Sevenless'
    Iversen, Lars
    Tu, Hsiung-Lin
    Lin, Wan-Chen
    Iwig, Jeffrey
    Gureasko, Jodi
    Kuriyan, John
    Groves, Jay T.
    BIOPHYSICAL JOURNAL, 2011, 100 (03) : 256 - 256
  • [28] Progress in targeting RAS with small molecule drugs
    McCormick, Frank
    BIOCHEMICAL JOURNAL, 2019, 476 : 365 - 374
  • [29] Design and Structural Optimization of Orally Bioavailable SOS1 Inhibitors for the Treatment of KRAS-Driven Carcinoma
    Zhang, Silong
    Zhang, Yu
    Chen, Xin
    Xu, Juan
    Fang, Huaxiang
    Li, Yuanyuan
    Liu, Yi
    He, Huan
    JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (23) : 15856 - 15877
  • [30] An updated patent review of SOS1 inhibitors (2022-present)
    Zhou, Guizhen
    Zhou, Chuan
    Ma, Xinyi
    Xu, Jiahang
    Zhou, Zehui
    Xu, Tianfeng
    Zheng, Mingyue
    Zhang, Sulin
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2024, 34 (12) : 1199 - 1213